

Amendments to the Claims

1. (currently amended) A method of ~~reducing mortality and morbidity after~~ treating stroke, comprising administering an effective amount of ~~to a patient in need thereof~~, a compound selected from the group consisting of GLP-1, GLP-1 analogs, GLP-1 derivatives, and pharmaceutically-acceptable salts thereof, to a patient in need thereof. ~~at a dose effective to normalize blood glucose.~~
2. (original) The method of claim 1, wherein the compound is administered intravenously.
3. (original) The method of claim 1, wherein the compound is administered subcutaneously.
4. (original) The method of claims 2 or 3, wherein the administration is continuous.
5. (original) The method of claim 4 wherein the rate of administration of the compound is between 0.25 and 6 pmol/kg/min.
6. (original) The method of claim 5 wherein the rate of administration of the compound is between 0.5 and 2.4 pmol/kg/min.
7. (original) The method of claim 5 wherein said rate is between about 0.5 and about 1.2 pmol/kg/min.
8. (original) The method of claim 2 wherein the intravenous administration is intermittent.
9. (original) The method of claim 2 wherein the compound is administered intravenously and also administered by another parenteral route.
10. (original) The method of claim 9 wherein the other parenteral route is the subcutaneous route.
11. (currently amended) The method of claim 1 wherein the compound administered is GLP-1(7-36) amide, or a pharmaceutically-acceptable salt thereof.
12. (currently amended) A method of ~~reducing morbidity and mortality after~~ treating stroke, comprising, administering an effective amount of a compound that exerts insulintropic activity by interacting with the same receptor, or receptors, with which GLP-1, GLP-1 analogs, and GLP-1 derivatives interact in exerting their insulintropic activity to a patient in need thereof.

Serial No. 09/400,802

- 13. (cancelled)
- 14. (cancelled)
- 15. (cancelled)